Ventana, Biocare ink agreement for p63 technology
TUSCON, Ariz.—Ventana Medical Systems Inc., a member of the Roche Group, and Biocare Medical LLC have announced the signing of a non-exclusive license agreement under which Biocare will gain access to certain patents and materials related to p63 diagnostics in the research and in-vitro diagnostics (IVD) field. No financial details were released. In conjunction with the agreement, Biocare and AsymmetRx Medical Inc. have reached a settlement regarding the p63 technology, for which AsymmetRx holds the exclusive worldwide license under the Harvard Medical School patent filings for use of the p63 antibody to aid in diagnosing prostate and other cancers. Part of the settlement involves Biocare gaining a worldwide license through Ventana to distribute p63 (4A4) mouse monoclonal primary antibody in the research and IVD markets.